IATDMCT 2017

Session information

Print

Oral

[O27-4] O27-4: Oncology (2)

Wed. Sep 27, 2017 2:30 PM - 3:30 PM Room C1 (1F)

Chairs: Takayasu Kurata, Japan / Etienne Chatelut, France

[O27-4-2] Population pharmacokinetic modeling of alemtuzumab in pediatric patients undergoing allogeneic hematopoietic cell transplantation for non-malignant diseases

Tsuyoshi Fukuda1, Chie Emoto2, Rebecca A. Marsh3, Lisa Neumeier4, Parinda A. Mehta5, Alexander A. Vinks6 (1.Cincinnati Children's Hospital Medical Center, 2.Cincinnati Children's Hospital Medical Center, 3.Cincinnati Children's Hospital Medical Center, 4.Cincinnati Children's Hospital Medical Center, 5.Cincinnati Children's Hospital Medical Center, 6.Cincinnati Children's Hospital Medical Center)

[O27-4-3] The effects of advanced age and serum alpha1-acid glycoprotein on Docetaxel unbound exposure and dose-limiting toxicity in cancer patients

Hirotsugu Kenmotsu1, Chiyo K. Imamura2, Akira Ono3, Shota Omori4, Kazuhisa Nakashima5, Kazushige Wakuda6, Tetsuhiko Taira7, Tateaki Naito8, Murakami Haruyasu9, Takahashi Toshiaki10, Yusuke Tanigawara11 (1.Shizuoka Cancer Center, 2.Keio University School of Medicine, 3.Shizuoka Cancer Center, 4.Shizuoka Cancer Center, 5.Shizuoka Cancer Center, 6.Shizuoka Cancer Center, 7.Shizuoka Cancer Center, 8.Shizuoka Cancer Center, 9.Shizuoka Cancer Center, 10.Shizuoka Cancer Center, 11.Keio University School of Medicine)

[O27-4-4] UGT1A1 polymorphism may be a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan

Tomoko Yoshihama1, Akira Hirasawa2, Hiroyuki Nomura3, Tomoko Akahane4, Yoshiko Nanki5, Wataru Yamagami6, Fumio Kataoka7, Eiichiro Tominaga8, Nobuyuki Susumu9, Taisei Mushiroda10, Daisuke Aoki11 (1.Keio University, 2.Keio University, 3.Keio University, 4.Keio University, 5.Keio University, 6.Keio University, 7.Keio University, 8.Keio University, 9.Keio University, 10.RIKEN Center for Integrative Medical Sciences, 11.Keio University)